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The basis of this change is multifactorial, including modifications in surgical technique and improvements in chemotherapy and radiotherapy. However, the ideal combination of treatment modalities remains controversial.
Several trials in the past decade have shown the benefit of additional therapies. A US Intergroup Trial demonstrated increased survival time among patients receiving adjuvant chemoradiotherapy versus observation after resection. 2 The British MAGIC trial further showed the benefit of perioperative chemotherapy, demonstrating an improved 5-year survival compared to observation after surgery. 3 The results of these trials have led the United Kingdom and parts of Europe to adopt the perioperative chemotherapy regimen, while the United States continues to primarily use adjuvant chemoradiotherapy. 4, 5 Little is known about how widely these protocols have been adopted since the publications acknowledging their efficacy. Using the National Cancer Data Base (NCDB), we evaluated trends in the surgical treatment of gastric adenocarcinoma at American cancer centers between 2000 and 2009.
METHODS
The NCDB is a national oncology outcomes database for over 1,500 Commission on Cancer-accredited cancer programs. The NCDB is a joint program of the American College of Surgeon's Commission on Cancer and the American Cancer Society. Institutional review board approval was received from our institution to access the database, which was accessed on March 15, 2013 6, 7 Attention was paid to the initial treatment regimen. The NCDB does not identify the timing of therapies received in addition to surgery. Surgery plus radiotherapy and chemotherapy is referred to interchangeably as ''chemoradiotherapy.'' We designated ''nonsurgical therapy'' to include chemotherapy only, chemoradiotherapy only, or no first-course treatment. The NCDB categorizes patients as receiving ''other specified therapy'' when the first course of treatment does not fall under any of the above-mentioned categories.
We defined private insurance as including managed care or any private insurance. Patient comorbidities are recorded in the NCDB according to the Charlson comorbidity score using the Deyo method of mapping administrative codes. Data regarding hospital setting were analyzed. The NCDB defined teaching/research hospitals as facilities associated with university medical schools or are designated as National Cancer Institute Comprehensive Cancer Care programs. Teaching/research hospitals make up 18 % of the reporting hospitals and account for 33 % of cases in the NCDB. The NCDB defines community cancer centers as facilities that diagnose or treat 100-649 cancer cases annually and comprehensive community cancer centers as facilities that treat 650 or more cancer cases annually. In this study, we considered community and comprehensive community cancer centers together; we refer to them generally as ''community hospitals.'' Community hospitals make up 74 % of all reporting hospitals and account for 63 % of cases in the NCDB. Hospitals that do not fulfill these criteria were categorized as ''other'' and make up the remaining portion of reporting hospitals in the NCDB.
We 
RESULTS

Demographics
A total of 50,778 patients with stage I-III gastric adenocarcinoma were included in the study. Patient demographics at community and teaching hospitals are shown in Table 1 . With the exception of cancer stage, all demographics varied significantly between community and teaching hospitals (p \ 0.0001 for all). Notable differences included an older population with a higher portion of patients with a Charlson Comorbidity Score of 2 or greater receiving treatment at community hospitals.
Surgery as Treatment of Gastric Adenocarcinoma
From 2000 to 2009, the use of surgery as a component of treatment of stage I-III disease decreased significantly at both community hospitals (p \ 0.0001 for all) and teaching hospitals during the study period (p \ 0.01 for all). In 2009, 64.2 % of stage I patients at community hospitals received surgery compared to 76.2 % at teaching hospitals (p \ 0.0001) (Fig. 1a) . In that same year, 69.2 % of stage II patients received surgery at community hospitals compared to 72.8 % at teaching hospitals (p = 0.15) (Fig. 1b) . Of all stage III patients in 2009, 68.2 % received surgery at community hospitals compared to 65.2 % at teaching hospitals (p = 0.2) (Fig. 1c) .
Use of Surgery Alone
The use of surgery alone decreased significantly for stage I-III disease at both community and teaching hos- 
Use of Surgery Plus Chemotherapy
The use of chemotherapy in addition to surgery increased significantly for stage I-III disease at both community and teaching hospitals during the study period (p \ 0.0001 for all). Of all stage I patients who underwent surgery at community hospitals in 2009, 7.9 % received additional chemotherapy, a 4.1 % increase from 2000. Likewise, of stage I patients who underwent surgery at teaching hospitals in 2009, 11.5 % received additional chemotherapy, a 7.8 % increase since 2000 (Fig. 2a) (Fig. 2b) . Similar increases were seen for stage III disease, with 18.4 % of community hospitals patients receiving surgery plus chemotherapy in 2009 (7.4 % increase) compared to 26.8 % of teaching hospitals patients (15.5 % increase) (Fig. 2c) . In 2009, patients with stage I-III disease received chemotherapy in addition to surgery more frequently at teaching hospitals compared to community hospitals (p \ 0.05 for all three).
Use of Surgery, Radiotherapy, and Chemotherapy
The use of surgery in combination with chemoradiotherapy (S?CRT) increased for stage I-III disease at community hospitals during the study period (p \ 0.05 for all). Of all stage I patients who underwent surgery at community hospitals in 2009, 19.7 % received S?CRT, a 6.7 % increase since 2000 (Fig. 2a) . Likewise, of stage II patients who received surgery at community hospitals, 44.1 % received S?CRT in 2009 (11.1 % increase) (Fig. 2b) . Of stage III patients who received surgery at community hospitals, 47.6 % received S?CRT in 2009 (5.1 % increase) (Fig. 2c) . Although the fraction of stage I-III patients at teaching hospitals who received S?CRT was comparable to that of community hospitals, only stage II disease saw a significant increase in the use of S?CRT (p \ 0.01). Of stage II patients who underwent surgery at teaching hospitals in 2009, 45.8 % received S?CRT, a 9.3 % increase since 2000. In 2009, the rate of surgery in combination with chemoradiotherapy for treatment of stage I-III disease did not differ significantly between community and teaching hospitals.
Use of Nonsurgical Therapy
The use of nonsurgical therapy (NST) for stages I-III gastric adenocarcinoma increased significantly at both community and teaching hospitals during the study period (p \ 0.001 for all). A total of 31.3 % of stage I patients at significant increase in the use of surgery plus chemotherapy as well as a significant decrease in the use of surgery alone for stage I-III disease. The use of surgery plus chemoradiotherapy continued to increase at community hospitals. However, the use of NST for treatment of resectable gastric adenocarcinoma increased. Previous publications have demonstrated improved patient survival with the addition of adjuvant or neoadjuvant therapy compared to observation after surgery. 2, 3, 9, 10 Given the evidence in favor of therapy in additional to surgery, it would be expected that the use of surgery alone for treatment of resectable gastric adenocarcinoma is declining, with the exception of patients with stage IA disease, who were not included in either the Intergroup or MAGIC trial. Sherman Cunningham and colleagues demonstrated improved overall survival with perioperative chemotherapy. 3 Sherman et al. demonstrated an increased use of neoadjuvant therapy, from 5.9 % in 1998 to 20.0 % in 2007. 11 Because the NCDB data accessed for the current study does not distinguish between adjuvant and neoadjuvant therapy, the designation of surgery plus chemotherapy is most appropriate in this comparison. In our study, the use of surgery plus chemotherapy increased significantly for stage I-III disease at both teaching and community hospitals between 2000 and 2009. Moreover, teaching hospitals utilized surgery plus chemotherapy more often than community hospitals for all three stages of disease. However, patients who received chemotherapy alone represent a minority proportion of patients, potentially as a result of slow implementation of MAGIC trial results or a preference for the use of radiotherapy as a component of therapy. In 2000, we found that among patients who received any therapy in addition to surgery, only 21 % received chemotherapy (stage I-III). However, by 2009, this portion had increased to a range of 30-35 %, indicating a shift in treatment paradigms. Recent trials continue to validate the efficacy of neoadjuvant and perioperative chemotherapy and have likely contributed to the increased use of chemotherapy in addition to surgery among American clinicians. 16, 17 The current study also demonstrates the more troubling finding that the use of NST for resectable gastric adenocarcinoma is increasing. The use of NST increased significantly at both community and teaching hospitals between 2000 and 2009. There was at least an 11 % increase in NST at both hospital settings, with the exception of stage I patients at teaching hospitals, which showed only a 3.2 % increase. Potential explanations for this finding are an aging patient population with increased comorbidities who are not suitable for surgery, as well as prolonged toxicity from preoperative therapy. The reasons for the increase in nonsurgical treatment could not be further explored using this data set.
This study is subject to several limitations. First, the NCDB does not distinguish between adjuvant or neoadjuvant treatments that patients receive or specify specific treatment protocols for chemotherapy or radiotherapy. As a result, generalizing conclusions from this study may result in small inaccuracies. However, given the large number of patients in the study, the overwhelming power of the study limits this factor. Second, the NCDB does not distinguish between stage IA or IB gastric adenocarcinoma, and as a result both patient populations were included in our analysis. Moreover, the database does not specify the extent of lymph node resection or lymph node involvement. These factors directly affect the treatment that is selected for each patient, and as a result, our data provide a less specific overview of current treatment trends.
In conclusion, the treatment of resectable gastric adenocarcinoma is continually changing in the United States. An increasing proportion of patients are receiving chemotherapy or chemoradiotherapy in addition to surgery with a concomitant decline in the utilization of surgery alone. However, there appears to be an increasing utilization of NST for resectable gastric adenocarcinoma.
